Loading…
Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast
Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overc...
Saved in:
Published in: | Pharmaceuticals (Basel, Switzerland) Switzerland), 2024-10, Vol.17 (11), p.1415 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c429t-7e2c9f4e0022c87402ae16674c18c69ed71ff562e42ddaceeb7a1796d7b30e243 |
container_end_page | |
container_issue | 11 |
container_start_page | 1415 |
container_title | Pharmaceuticals (Basel, Switzerland) |
container_volume | 17 |
creator | Jeong, Ji-Su Ha, Eun-Sol Park, Heejun Lee, Seon-Kwang Kang, Hui-Taek Kim, Min-Soo |
description | Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overcome the instability of lifitegrast by developing a more stable eyedrop formulation by using citric acid and tromethamine to prevent the degradation of lifitegrast.
Based on the Design of Experiment (DoE) approach, formulations were prepared at various concentrations of two stabilizers, citric acid and tromethamine. The stabilizers were carefully controlled to reduce the generation of degradation products. The eyedrops were stored under accelerated test conditions, and parameters such as appearance, pH, drug content, and impurities were evaluated.
The results showed that all critical quality attributes (CQAs) including appearance, pH, drug content, and impurities were maintained at stable levels under accelerated conditions, meeting established criteria. In addition, it was suggested that citric acid provided protection against oxidative stress, while tromethamine prevented hydrolysis caused by pH fluctuations.
Consequently, it was concluded that the developed lifitegrast-containing eyedrop formulation exhibited improved physicochemical stability, validated through statistical analyses. These findings contribute to the development of stable eyedrops and provide a foundation for commercial production and clinical applications. |
doi_str_mv | 10.3390/ph17111415 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9f68a78089a0440a989f6263c71be275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A818467891</galeid><doaj_id>oai_doaj_org_article_9f68a78089a0440a989f6263c71be275</doaj_id><sourcerecordid>A818467891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-7e2c9f4e0022c87402ae16674c18c69ed71ff562e42ddaceeb7a1796d7b30e243</originalsourceid><addsrcrecordid>eNptks-LEzEUgAdR3LV68Q-QAS8idM2vmSQnKaXqQsGD68VLyGRepikzSU1Sof-96XZdW5EcXnj53hfe41XVa4xuKJXow26DOcaY4eZJdY0ZYXNBGH96dr-qXqS0RajhhXpeXVHZSEEJv65-rKwFk-tg66XL0Zl6YVxfa9_XdzFMkDd6ch7q4Ou8gfpb1p0bXT4cC1YH6GPYpXoZfNbOOz_Ua2ddhiHqlF9Wz6weE7x6iLPq-6fV3fLLfP318-1ysZ4bRmSecyBGWgYIEWIEZ4howG3LmcHCtBJ6jq1tWgKM9L02AB3XmMu25x1FQBidVbcnbx_0Vu2im3Q8qKCduk-EOCgdszMjKGlboblAQmrEGNJSlAxpqeG4A8Kb4vp4cu323QS9AZ-jHi-kly_ebdQQfimMG8kF4cXw7sEQw889pKwmlwyMo_YQ9klRTClrES5xVr39B92GffRlVvcUJlLwM2rQpQPnbSgfm6NULQQWrOVCHqmb_1Dl9DA5EzxYV_IXBe9PBSaGlCLYxyYxUse1Un_XqsBvzsfyiP7ZI_obldzFRA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3133129871</pqid></control><display><type>article</type><title>Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Jeong, Ji-Su ; Ha, Eun-Sol ; Park, Heejun ; Lee, Seon-Kwang ; Kang, Hui-Taek ; Kim, Min-Soo</creator><creatorcontrib>Jeong, Ji-Su ; Ha, Eun-Sol ; Park, Heejun ; Lee, Seon-Kwang ; Kang, Hui-Taek ; Kim, Min-Soo</creatorcontrib><description>Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overcome the instability of lifitegrast by developing a more stable eyedrop formulation by using citric acid and tromethamine to prevent the degradation of lifitegrast.
Based on the Design of Experiment (DoE) approach, formulations were prepared at various concentrations of two stabilizers, citric acid and tromethamine. The stabilizers were carefully controlled to reduce the generation of degradation products. The eyedrops were stored under accelerated test conditions, and parameters such as appearance, pH, drug content, and impurities were evaluated.
The results showed that all critical quality attributes (CQAs) including appearance, pH, drug content, and impurities were maintained at stable levels under accelerated conditions, meeting established criteria. In addition, it was suggested that citric acid provided protection against oxidative stress, while tromethamine prevented hydrolysis caused by pH fluctuations.
Consequently, it was concluded that the developed lifitegrast-containing eyedrop formulation exhibited improved physicochemical stability, validated through statistical analyses. These findings contribute to the development of stable eyedrops and provide a foundation for commercial production and clinical applications.</description><identifier>ISSN: 1424-8247</identifier><identifier>EISSN: 1424-8247</identifier><identifier>DOI: 10.3390/ph17111415</identifier><identifier>PMID: 39598327</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acids ; Antioxidants ; Care and treatment ; Citric acid ; Complications and side effects ; Design of experiments ; Diagnosis ; Dosage and administration ; Drug therapy ; dry eye disease ; Dry eye syndromes ; Eye diseases ; eyedrop formulation ; FDA approval ; Inflammation ; lifitegrast ; Oxidation ; Oxidative stress ; physicochemical stability</subject><ispartof>Pharmaceuticals (Basel, Switzerland), 2024-10, Vol.17 (11), p.1415</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c429t-7e2c9f4e0022c87402ae16674c18c69ed71ff562e42ddaceeb7a1796d7b30e243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3133129871/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3133129871?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39598327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jeong, Ji-Su</creatorcontrib><creatorcontrib>Ha, Eun-Sol</creatorcontrib><creatorcontrib>Park, Heejun</creatorcontrib><creatorcontrib>Lee, Seon-Kwang</creatorcontrib><creatorcontrib>Kang, Hui-Taek</creatorcontrib><creatorcontrib>Kim, Min-Soo</creatorcontrib><title>Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast</title><title>Pharmaceuticals (Basel, Switzerland)</title><addtitle>Pharmaceuticals (Basel)</addtitle><description>Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overcome the instability of lifitegrast by developing a more stable eyedrop formulation by using citric acid and tromethamine to prevent the degradation of lifitegrast.
Based on the Design of Experiment (DoE) approach, formulations were prepared at various concentrations of two stabilizers, citric acid and tromethamine. The stabilizers were carefully controlled to reduce the generation of degradation products. The eyedrops were stored under accelerated test conditions, and parameters such as appearance, pH, drug content, and impurities were evaluated.
The results showed that all critical quality attributes (CQAs) including appearance, pH, drug content, and impurities were maintained at stable levels under accelerated conditions, meeting established criteria. In addition, it was suggested that citric acid provided protection against oxidative stress, while tromethamine prevented hydrolysis caused by pH fluctuations.
Consequently, it was concluded that the developed lifitegrast-containing eyedrop formulation exhibited improved physicochemical stability, validated through statistical analyses. These findings contribute to the development of stable eyedrops and provide a foundation for commercial production and clinical applications.</description><subject>Acids</subject><subject>Antioxidants</subject><subject>Care and treatment</subject><subject>Citric acid</subject><subject>Complications and side effects</subject><subject>Design of experiments</subject><subject>Diagnosis</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>dry eye disease</subject><subject>Dry eye syndromes</subject><subject>Eye diseases</subject><subject>eyedrop formulation</subject><subject>FDA approval</subject><subject>Inflammation</subject><subject>lifitegrast</subject><subject>Oxidation</subject><subject>Oxidative stress</subject><subject>physicochemical stability</subject><issn>1424-8247</issn><issn>1424-8247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks-LEzEUgAdR3LV68Q-QAS8idM2vmSQnKaXqQsGD68VLyGRepikzSU1Sof-96XZdW5EcXnj53hfe41XVa4xuKJXow26DOcaY4eZJdY0ZYXNBGH96dr-qXqS0RajhhXpeXVHZSEEJv65-rKwFk-tg66XL0Zl6YVxfa9_XdzFMkDd6ch7q4Ou8gfpb1p0bXT4cC1YH6GPYpXoZfNbOOz_Ua2ddhiHqlF9Wz6weE7x6iLPq-6fV3fLLfP318-1ysZ4bRmSecyBGWgYIEWIEZ4howG3LmcHCtBJ6jq1tWgKM9L02AB3XmMu25x1FQBidVbcnbx_0Vu2im3Q8qKCduk-EOCgdszMjKGlboblAQmrEGNJSlAxpqeG4A8Kb4vp4cu323QS9AZ-jHi-kly_ebdQQfimMG8kF4cXw7sEQw889pKwmlwyMo_YQ9klRTClrES5xVr39B92GffRlVvcUJlLwM2rQpQPnbSgfm6NULQQWrOVCHqmb_1Dl9DA5EzxYV_IXBe9PBSaGlCLYxyYxUse1Un_XqsBvzsfyiP7ZI_obldzFRA</recordid><startdate>20241023</startdate><enddate>20241023</enddate><creator>Jeong, Ji-Su</creator><creator>Ha, Eun-Sol</creator><creator>Park, Heejun</creator><creator>Lee, Seon-Kwang</creator><creator>Kang, Hui-Taek</creator><creator>Kim, Min-Soo</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20241023</creationdate><title>Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast</title><author>Jeong, Ji-Su ; Ha, Eun-Sol ; Park, Heejun ; Lee, Seon-Kwang ; Kang, Hui-Taek ; Kim, Min-Soo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-7e2c9f4e0022c87402ae16674c18c69ed71ff562e42ddaceeb7a1796d7b30e243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acids</topic><topic>Antioxidants</topic><topic>Care and treatment</topic><topic>Citric acid</topic><topic>Complications and side effects</topic><topic>Design of experiments</topic><topic>Diagnosis</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>dry eye disease</topic><topic>Dry eye syndromes</topic><topic>Eye diseases</topic><topic>eyedrop formulation</topic><topic>FDA approval</topic><topic>Inflammation</topic><topic>lifitegrast</topic><topic>Oxidation</topic><topic>Oxidative stress</topic><topic>physicochemical stability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jeong, Ji-Su</creatorcontrib><creatorcontrib>Ha, Eun-Sol</creatorcontrib><creatorcontrib>Park, Heejun</creatorcontrib><creatorcontrib>Lee, Seon-Kwang</creatorcontrib><creatorcontrib>Kang, Hui-Taek</creatorcontrib><creatorcontrib>Kim, Min-Soo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJÂ Directory of Open Access Journals</collection><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jeong, Ji-Su</au><au>Ha, Eun-Sol</au><au>Park, Heejun</au><au>Lee, Seon-Kwang</au><au>Kang, Hui-Taek</au><au>Kim, Min-Soo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast</atitle><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle><addtitle>Pharmaceuticals (Basel)</addtitle><date>2024-10-23</date><risdate>2024</risdate><volume>17</volume><issue>11</issue><spage>1415</spage><pages>1415-</pages><issn>1424-8247</issn><eissn>1424-8247</eissn><abstract>Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overcome the instability of lifitegrast by developing a more stable eyedrop formulation by using citric acid and tromethamine to prevent the degradation of lifitegrast.
Based on the Design of Experiment (DoE) approach, formulations were prepared at various concentrations of two stabilizers, citric acid and tromethamine. The stabilizers were carefully controlled to reduce the generation of degradation products. The eyedrops were stored under accelerated test conditions, and parameters such as appearance, pH, drug content, and impurities were evaluated.
The results showed that all critical quality attributes (CQAs) including appearance, pH, drug content, and impurities were maintained at stable levels under accelerated conditions, meeting established criteria. In addition, it was suggested that citric acid provided protection against oxidative stress, while tromethamine prevented hydrolysis caused by pH fluctuations.
Consequently, it was concluded that the developed lifitegrast-containing eyedrop formulation exhibited improved physicochemical stability, validated through statistical analyses. These findings contribute to the development of stable eyedrops and provide a foundation for commercial production and clinical applications.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39598327</pmid><doi>10.3390/ph17111415</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1424-8247 |
ispartof | Pharmaceuticals (Basel, Switzerland), 2024-10, Vol.17 (11), p.1415 |
issn | 1424-8247 1424-8247 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_9f68a78089a0440a989f6263c71be275 |
source | Publicly Available Content Database; PubMed Central |
subjects | Acids Antioxidants Care and treatment Citric acid Complications and side effects Design of experiments Diagnosis Dosage and administration Drug therapy dry eye disease Dry eye syndromes Eye diseases eyedrop formulation FDA approval Inflammation lifitegrast Oxidation Oxidative stress physicochemical stability |
title | Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A22%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Citric%20Acid%20and%20Tromethamine%20on%20the%20Stability%20of%20Eyedrops%20Containing%20Lifitegrast&rft.jtitle=Pharmaceuticals%20(Basel,%20Switzerland)&rft.au=Jeong,%20Ji-Su&rft.date=2024-10-23&rft.volume=17&rft.issue=11&rft.spage=1415&rft.pages=1415-&rft.issn=1424-8247&rft.eissn=1424-8247&rft_id=info:doi/10.3390/ph17111415&rft_dat=%3Cgale_doaj_%3EA818467891%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c429t-7e2c9f4e0022c87402ae16674c18c69ed71ff562e42ddaceeb7a1796d7b30e243%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3133129871&rft_id=info:pmid/39598327&rft_galeid=A818467891&rfr_iscdi=true |